Virus and radiation combo takes aim at rare sarcomas

NCT ID NCT04599062

Ongoing Disease control Sponsor: John Rieth Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests whether injecting a cancer-fighting virus (T-VEC) directly into tumors, along with standard radiation, is safe and tolerable for people with advanced soft tissue sarcoma. About 8 participants will receive the combination before surgery. The study primarily looks for side effects and how much tumor tissue dies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Talimogene laherparepvec (T-VEC), a modified herpes virus that attacks cancer cells, plus radiation therapy
What this could lead to: If successful, this combination could shrink sarcomas enough to allow complete surgical removal, potentially improving local control and survival.
What could go wrong: This is a very early, small Phase 1/2 trial with only 8 participants. The main goal is safety, not effectiveness. Side effects from the virus or radiation could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOFT TISSUE SARCOMA

Contacts and locations

Locations

University of Iowa Hospitals and Clinics

Iowa City, Iowa, 52242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.